Hehlmann R, Lauseker M, Saussele S. et al. Final Evaluation of Randomized CML-Study IV: 10-Year Survival and Evolution of Terminal Phase. ASH 59th Annual Meeting & Exhibition, abstract 897.
Moet ibrutinib de nieuwe standaard worden bij de behandeling van CLL?
apr 2020 | Leukemie